Search Results - anna+reister+schultz

2 Results

Sort By:

Novel single-gene biomarker for acute myeloid leukemia prognosis

Summary The current technology is a novel set of biomarkers derived from the largest ever genomic and transcriptomic data set for acute myeloid leukemia (AML), which includes a novel single gene biomarker capable of strongly predicting AML prognosis. Technology Overview Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with an incidence...

Published: 9/27/2023 | Inventor(s): Daniel Bottomly, Brian Druker, Kara Johnson, Stephen (Steve) Kurtz, Nicola Long, Shannon McWeeney, Anna Reister Schultz, Cristina Tognon, Jeffrey (Jeff) Tyner

Keywords(s): Diagnostics, Diagnostics - Cancer

Category(s): Diagnostics

Mutation-specific treatment strategies for acute myeloid leukemia

Summary The implementation of targeted therapies for acute myeloid leukemia (AML) has been challenged by complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Oregon Health & Science University (OHSU) researchers have identified treatment strategies for a broad scope of AML...

Published: 10/3/2022 | Inventor(s): Jeffrey Tyner, Cristina Tognon, Brian Druker, Daniel Bottomly, Beth Wilmot, Stephen (Steve) Kurtz, Samantha Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Shannon McWeeney

Keywords(s): Diagnostics, Diagnostics - Cancer, Therapeutics, Therapeutics - Cancer

Category(s): Therapeutics, Diagnostics